CompletedNot Applicable

Intravenous Enhancin[Co-amoxiclav] Versus Postoperative Enhancin in Prevention of Postadenotonsillectomy Morbidity.

Kenya126 participantsStarted 2008-05

Plain-language summary

Null hypothesis; The efficacy of Enhancin\]Co-Amoxiclav given as a single intravenous dose at induction is not better than a five days oral course of the same given postoperatively in reducing postoperative morbidity after adenotonsillectomy.

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients below 12year scheduled to undergo adenotonsillectomy whose parents or guardians give consent for recruitment into the study. Exclusion Criteria: * Non consenting parents or guardians. Antibiotic use in the week preceding surgery. Patients with co mordities. Known allergies to Co-amoxiclav. Patients who develop complication that warrant change of antibiotic.

What they're measuring

POSTOPERATIVE FEVER

Timeframe: OPERATION DAY TO 7 DAYS POSTOPERATIVELY

Trial details

NCT IDNCT01267942

SponsorUniversity of Nairobi

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-10

View on ClinicalTrials.gov More Adenotonsillar Hypertrophy,Under 12 Years. trials